Literature DB >> 7404319

The technique of popliteal lymph node dissection.

C P Karakousis.   

Abstract

Popliteal node dissection may be indicated when in continuity dissection is performed along with the excision of a primary malignant tumor adjacent to the popliteal fossa or when actual or potential metastatic disease to the popliteal nodes is suspected. The technique involves removal of fatty tissue and nodes of the popliteal fossa with proper identification and preservation of the common peroneal and tibial nerves and popliteal vessels.

Entities:  

Mesh:

Year:  1980        PMID: 7404319

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  5 in total

1.  Popliteal lymphadenectomy on sentinel lymph node melanoma metastasis.

Authors:  Antonio Barrasa Shaw; Francisca Sancho Merle; Carlos Fuster Diana; Jorge Campos Máñez; Carlos Vázquez Albadalejo
Journal:  Clin Transl Oncol       Date:  2006-03       Impact factor: 3.405

2.  Management of popliteal sentinel nodes in melanoma.

Authors:  Shawn T Steen; Hamed Kargozaran; Christopher J Moran; Myung Shin-Sim; Donald L Morton; Mark B Faries
Journal:  J Am Coll Surg       Date:  2011-03-26       Impact factor: 6.113

3.  Popliteal lymph node dissection for metastatic squamous cell carcinoma: a case report of an uncommon procedure for an uncommon presentation.

Authors:  Basem B Morcos; Sameh Hashem; Firas Al-Ahmad
Journal:  World J Surg Oncol       Date:  2011-10-15       Impact factor: 2.754

4.  Resection in the popliteal fossa for metastatic melanoma.

Authors:  Ugo Marone; Corrado Caracò; Maria Grazia Chiofalo; Gerardo Botti; Nicola Mozzillo
Journal:  World J Surg Oncol       Date:  2007-01-19       Impact factor: 2.754

5.  Popliteal lymph node dissection for metastases of cutaneous malignant melanoma.

Authors:  Frederico Teixeira; Vitor Moutinho; Eduardo Akaishi; Gabriella Mendes; Andre Perina; Tiberio Lima; Margareth Lallee; Sergio Couto; Edivaldo Utiyama; Samir Rasslan
Journal:  World J Surg Oncol       Date:  2014-05-01       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.